A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors

Nature Chemical Biology

Volumn 10, Issue 9, 2014, Pages 760-767

  Lanning, Bryan R ^a   Whitby, Landon R ^a   Dix, Melissa M ^a   Douhan, John ^b   Gilbert, Adam M ^b   Hett, Erik C ^b   Johnson, Theodore O ^b   Joslyn, Chris ^a   Kath, John C ^b   Niessen, Sherry ^b   Roberts, Lee R ^b   Schnute, Mark E ^b   Wang, Chu ^a   Hulce, Jonathan J ^a   Wei, Baoxian ^c   Whiteley, Laurence O ^b   Hayward, Matthew M ^b   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c Pfizer Global Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; CELL DEATH; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION;

CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE; GENES, ERBB-1; HUMANS; KINETICS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PROTEOME; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84906307152     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1582     Document Type: Article

References (54)

1. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
2. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005).
3. Liu, Q. et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20, 146-159 (2013).
4. Rosenblum, J.S., Nomanbhoy, T.K. & Kozarich, J.W. Functional interrogation of kinases and other nucleotide-binding proteins. FEBS Lett. 587, 1870-1877 (2013).
5. Krishnamurty, R. & Maly, D.J. Chemical genomic and proteomic methods for determining kinase inhibitor selectivity. Comb. Chem. High Throughput Screen. 10, 652-666 (2007).
6. Rix, U. & Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616-624 (2009).
7. Singh, J., Petter, R.C. & Kluge, A.F. Targeted covalent drugs of the kinase family. Curr. Opin. Chem. Biol. 14, 475-480 (2010).
8. Carmi, C., Mor, M., Petronini, P.G. & Alfieri, R.R. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. 84, 1388-1399 (2012).
9. Barf, T. & Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem. 55, 6243-6262 (2012).
10. Johnson, D.S., Weerapana, E. & Cravatt, B.F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2, 949-964 (2010).
11. Potashman, M.H. & Duggan, M.E. Covalent modifiers: an orthogonal approach to drug design. J. Med. Chem. 52, 1231-1246 (2009).
12. Cohen, M.S., Zhang, C., Shokat, K.M. & Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321 (2005).
13. Leproult, E., Barluenga, S., Moras, D., Wurtz, J.M. & Winssinger, N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J. Med. Chem. 54, 1347-1355 (2011).
14. Nelson, V., Ziehr, J., Agulnik, M. & Johnson, M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco. Targets Ther. 6, 135-143 (2013).
15. Cameron, F. & Sanford, M. Ibrutinib: first global approval. Drugs 74, 263-271 (2014).
16. Blair, J.A. et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat. Chem. Biol. 3, 229-238 (2007).
17. Cohen, M.S., Hadjivassiliou, H. & Taunton, J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat. Chem. Biol. 3, 156-160 (2007).
18. Honigberg, L.A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 107, 13075-13080 (2010).
19. Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790-795 (2010).
20. Pace, N.J. & Weerapana, E. Diverse functional roles of reactive cysteines. ACS Chem. Biol. 8, 283-296 (2013).
21. Shin, N.Y., Liu, Q., Stamer, S.L. & Liebler, D.C. Protein targets of reactive electrophiles in human liver microsomes. Chem. Res. Toxicol. 20, 859-867 (2007).
22. Cravatt, B.F., Wright, A.T. & Kozarich, J.W. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77, 383-414 (2008).
23. Smaill, J.B. et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 43, 1380-1397 (2000).
24. Rostovtsev, V.V., Green, J.G., Fokin, V.V. & Sharpless, K.B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. Int. Edn Engl. 41, 2596-2599 (2002).
25. Speers, A.E., Adam, G.C. & Cravatt, B.F. Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125, 4686-4687 (2003).
26. Mann, M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 7, 952-958 (2006).
27. Bachovchin, D.A. et al. Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc. Natl. Acad. Sci. USA 108, 6811-6816 (2011).
28. Adibekian, A. et al. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. Nat. Chem. Biol. 7, 469-478 (2011).
29. Hur, W. et al. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg. Med. Chem. Lett. 18, 5916-5919 (2008).
30. Pan, Z. et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2, 58-61 (2007).
31. Woyach, J.A. et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 123, 1207-1213 (2014).
32. Tsou, H.R. et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44, 2719-2734 (2001).
33. Li, D. et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702-4711 (2008).
34. Ponader, S. et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119, 1182-1189 (2012).
35. Kim, Y. et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 11, 784-791 (2012).
36. Simon, G.M., Niphakis, M.J. & Cravatt, B.F. Determining target engagement in living systems. Nat. Chem. Biol. 9, 200-205 (2013).
37. Nakayama, S. et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 37, 1970-1977 (2009).
38. Ahn, K. et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16, 411-420 (2009).
39. Chang, J.W., Cognetta, A.B. III, Niphakis, M.J. & Cravatt, B.F. Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition. ACS Chem. Biol. 8, 1590-1599 (2013).
40. Tsuboi, K. et al. Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance. J. Am. Chem. Soc. 133, 16605-16616 (2011).
41. Nishino, M. et al. Hypothemicin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei. eLife 2, e00712 (2013).
42. Yang, P.Y. et al. Activity-based proteome profiling of potential cellular targets of Orlistat-an FDA-approved drug with anti-tumor activities. J. Am. Chem. Soc. 132, 656-666 (2010).
43. Solca, F. et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343, 342-350 (2012).
44. Schwartz, P.A. et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc. Natl. Acad. Sci. USA 111, 173-178 (2014).
45. Herman, S.E. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117, 6287-6296 (2011).
46. Dasmahapatra, G. et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br. J. Haematol. 161, 43-56 (2013).
47. Rushworth, S.A. et al. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell. Signal. 25, 106-112 (2013).
48. Tai, Y.T. et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120, 1877-1887 (2012).
49. Hsu, K.L. et al. DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat. Chem. Biol. 8, 999-1007 (2012).
50. Weerapana, E., Simon, G.M. & Cravatt, B.F. Disparate proteome reactivity profiles of carbon electrophiles. Nat. Chem. Biol. 4, 405-407 (2008).
51. Hulce, J.J., Cognetta, A.B., Niphakis, M.J., Tully, S.E. & Cravatt, B.F. Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat. Methods 10, 259-264 (2013).
52. Martin, B.R., Wang, C., Adibekian, A., Tully, S.E. & Cravatt, B.F. Global profiling of dynamic protein palmitoylation. Nat. Methods 9, 84-89 (2012).
53. Washburn, M.P., Wolters, D. & Yates, J.R. III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242-247 (2001).
54. Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112-1116 (2006).